Clinical characteristics of lower respiratory infections in preterm children with bronchopulmonary dysplasia

Lee, Na Hyun; Kim, Se Jin; Choi, Hee Joung

doi:10.4168/aard.2017.5.2.92

Original Article

Open Access


Allergy Asthma Respir Dis. 2017 Mar;5(2):92-98. Korean. Published online March 31, 2017. https://doi.org/10.4168/aard.2017.5.2.92
© 2017 The Korean Academy of Pediatric Allergy and Respiratory Disease; The Korean Academy of Asthma, Allergy and Clinical Immunology


Clinical characteristics of lower respiratory infections in preterm children with bronchopulmonary dysplasia
Na Hyun Lee, Se Jin Kim and Hee Joung Choi
Department of Pediatrics, Keimyung University School of Medicine, Daegu, Korea.
Correspondence to: Hee Joung Choi. Department of Pediatrics, Keimyung University School of Medicine, 56 Dalseong-ro, Jung-gu, Daegu 41931, Korea. Tel: +82-53-250-7524, Fax: +82-53-250-7783, Email: joung756@dsmc.or.kr

Received July 29, 2016; Revised October 22, 2016; Accepted October 23, 2016.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/).

Go to: Abstract
Purpose We evaluated the clinical characteristics of lower respiratory infections of preterm children with bronchopulmonary dysplasia (BPD) and compared them between those with and without lower respiratory infections that of preterm patients without BPD. Methods This study enrolled preterm patients under 2 years old, who admitted with acute lower respiratory infection from March 2014 to May 2016. The patients were divided into 2 groups according to BPD, and we retrospectively reviewed their medical records. Results A total of 71 patients (106 cases) were enrolled; the BPD group consisited of 29 patients (54 cases) and the control group 42 patients (52 cases). Compared to the patients in the control group, those in the BPD group were older (P=0.001), had lower gestational age and birth weight (P<0.001), and showed more frequent readmission in hospital (P=0.017). The most common causative virus was human rhinovirus (hRV) in the BPD group, whereas respiratory syncytial virus (RSV) in the control group. The patients in the BPD group showed a higher incidence of tachypnea, decreased aeration, and chest retraction (P<0.001, P=0.009, and P=0.026, respectively), a higher respiratory symptom score (P=0.011), a longer duration of cough and wheezy sounds (P=0.004 and P=0.009, respectively), and higher incidence and longer duration of treatment with oxygen, and mechanical ventilator support (P=0.016 and P=0.017, respectively) than those in the control group. In the BPD group, the patients with RSV showed a higher incidence of tachypnea and rales (P=0.033 and P=0.033, respectively) than those with hRV. Conclusion The preterm children with BPD may have more severe clinical manifestations than those without.


Keywords: Bronchopulmonary dysplasia; Prematurity; Respiratory infection

Go to:

Figures


	Fig. 1 Proportion of repeated admission between groups. The proportion of repeated admission of bronchopulmonary dysplasia (BPD) group was significantly higher than control group.
	Click for larger imageDownload as PowerPoint slide


	Fig. 2 The causing viruses of lower respiratory tract infection according to bronchopulmonary dysplasia (BPD; A) and palivizumab prophylaxis in total group (B), BPD group (C) and control group (D). The most common causing virus was human rhinovirus (hRV) in BPD group, whereas respiratory syncytial virus (RSV) in control group. hMPV, human metapneumonvirus; PIV, parainfluenza virus; hBoV, human bocavirus; hCoV, human coronavirus; IFV, influenzavirus.
	Click for larger imageDownload as PowerPoint slide

Go to:

Tables


	Table 1 Comparison of clinical manifestations of patients
	Click for larger imageClick for full tableDownload as Excel file


	Table 2 Comparison of clinical manifestations of patients
	Click for larger imageClick for full tableDownload as Excel file


	Table 3 Comparison of laboratory findings of patients
	Click for larger imageClick for full tableDownload as Excel file


	Table 4 Comparison of in-hospital course of patients
	Click for larger imageClick for full tableDownload as Excel file

Go to:

References


1.	Northway WH Jr, Rosan RC, Porter DY. Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. N Engl J Med 1967;276:357–368.

2.	Coalson JJ. Pathology of bronchopulmonary dysplasia. Semin Perinatol 2006;30:179–184.

3.	Choi CW, Kim BI, Kim EK, Song ES, Lee JJ. Incidence of bronchopulmonary dysplasia in Korea. J Korean Med Sci 2012;27:914–921.

4.	Kim JK, Chang YS, Sung S, Ahn SY, Yoo HS, Park WS. Trends in Survival and Incidence of Bronchopulmonary Dysplasia in Extremely Preterm Infants at 23-26 Weeks Gestation. J Korean Med Sci 2016;31:423–429.

5.	Bhandari A, Panitch HB. Pulmonary outcomes in bronchopulmonary dysplasia. Semin Perinatol 2006;30:219–226.

6.	Aujard Y, Fauroux B. Risk factors for severe respiratory syncytial virus infection in infants. Respir Med 2002;96 Suppl B:S9–S14.

7.	Grimaldi M, Gouyon B, Michaut F, Huet F, Gouyon JB. Burgundy Perinatal Network. Severe respiratory syncytial virus bronchiolitis: epidemiologic variations associated with the initiation of palivizumab in severely premature infants with bronchopulmonary dysplasia. Pediatr Infect Dis J 2004;23:1081–1085.

8.	Morris SK, Dzolganovski B, Beyene J, Sung L. A meta-analysis of the effect of antibody therapy for the prevention of severe respiratory syncytial virus infection. BMC Infect Dis 2009;9:106.

9.	Resch B, Pasnocht A, Gusenleitner W, Müller W. Rehospitalisations for respiratory disease and respiratory syncytial virus infection in preterm infants of 29-36 weeks gestational age. J Infect 2005;50:397–403.

*10.*	García-Garcia ML, González-Carrasco E, Quevedo S, Muñoz C, Sánchez-Escudero V, Pozo F, et al. Clinical and virological characteristics of early and moderate preterm infants readmitted with viral respiratory infections. Pediatr Infect Dis J 2015;34:693–699.

*11.*	Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001;163:1723–1729.

*12.*	Pavón D, Castro-Rodríguez JA, Rubilar L, Girardi G. Relation between pulse oximetry and clinical score in children with acute wheezing less than 24 months of age. Pediatr Pulmonol 1999;27:423–427.

*13.*	Tal A, Bavilski C, Yohai D, Bearman JE, Gorodischer R, Moses SW. Dexamethasone and salbutamol in the treatment of acute wheezing in infants. Pediatrics 1983;71:13–18.

*14.*	Furman L, Baley J, Borawski-Clark E, Aucott S, Hack M. Hospitalization as a measure of morbidity among very low birth weight infants with chronic lung disease. J Pediatr 1996;128:447–452.

*15.*	Lee JH, Kim CS, Chang YS, Choi JH. Committee on Data Collection and Statistical Analysis of the Korean Society of Neonatology. Respiratory syncytial virus related readmission in preterm infants less than 34 weeks' gestation following discharge from a neonatal intensive care unit in Korea. J Korean Med Sci 2015;30 Suppl 1:S104–S110.

*16.*	Lee HJ, editor. Korean Pediatric Society. Immunization guideline. 7th ed. Seoul: Korean Pediatric Society; 2012. pp. 231-233.

*17.*	Carbonell-Estrany X, Quero J, Bustos G, Cotero A, Doménech E, Figueras-Aloy J, et al. IRIS Study Group. Rehospitalization because of respiratory syncytial virus infection in premature infants younger than 33 weeks of gestation: a prospective study. Pediatr Infect Dis J 2000;19:592–597.

*18.*	Park HW, Lee BS, Kim AR, Yoon HS, Kim BI, Song ES, et al. Epidemiology of respiratory syncytial virus infection in infants born at less than thirty-five weeks of gestational age. Pediatr Infect Dis J 2012;31:e99–e104.

*19.*	The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998;102(3 Pt 1):531–537.

*20.*	Pedraz C, Carbonell-Estrany X, Figueras-Aloy J, Quero J. IRIS Study Group. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants. Pediatr Infect Dis J 2003;22:823–827.

*21.*	Hervás D, Reina J, Yañez A, del Valle JM, Figuerola J, Hervás JA. Epidemiology of hospitalization for acute bronchiolitis in children: differences between RSV and non-RSV bronchiolitis. Eur J Clin Microbiol Infect Dis 2012;31:1975–1981.

*22.*	Miller EK, Bugna J, Libster R, Shepherd BE, Scalzo PM, Acosta PL, et al. Human rhinoviruses in severe respiratory disease in very low birth weight infants. Pediatrics 2012;129:e60–e67.